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Gene therapy with RALA/iNOS composite 
nanoparticles significantly enhances survival 
in a model of metastatic prostate cancer
Cian M. McCrudden1, John W. McBride1, Joanne McCaffrey1, Emma M. McErlean1, Nicholas J. Dunne2, 
Vicky L. Kett1, Jonathan A. Coulter1, Tracy Robson3 and Helen O. McCarthy1* 
Abstract 
Background: Recent approvals of gene therapies by the FDA and the EMA for treat-
ment of inherited disorders have further opened the door for assessment of nucleic 
acid pharmaceuticals for clinical usage. Arising from the presence of damaged or inap-
propriate DNA, cancer is a condition particularly suitable for genetic intervention. The 
RALA peptide has been shown to be a potent non-viral delivery platform for nucleic 
acids. This study examines the use of RALA to deliver a plasmid encoding inducible 
nitric oxide synthase (iNOS) as an anti-cancer treatment.
Methods: The physiochemical properties of the RALA/DNA nanoparticles were 
characterized via dynamic light scattering and transmission electron microscopy. The 
nanoparticles were labelled with fluorophores and tracked over time using confocal 
microscopy with orthogonal sections to determine cellular location. In vitro studies 
were employed to determine functionality of the nanoparticles both for pEGFP-N1 and 
CMV-iNOS. Nanoparticles were injected intravenously into C57/BL6 mice with blood 
and serum samples analysed for immune response. PC3-luc2M cells were injected into 
the left ventricle of SCID mice followed by treatment with RALA/CMV-iNOS nanoparti-
cles to evaluate the tumour response in a metastatic model of prostate cancer.
Results: Functional cationic nanoparticles were produced with gene expression in 
PC-3 prostate cancer cells. Furthermore, repeated administrations of RALA/DNA nano-
particles into immunocompetent mice did not produce any immunological response: 
neutralization of the vector or release of inflammatory mediators. RALA/CMV-iNOS 
reduced the clonogenicity of PC-3 cells in vitro, and in an in vivo model of prostate 
cancer metastasis, systemically delivered RALA/CMV-iNOS significantly improved the 
survival of mice.
Conclusion: These studies further validate RALA as a genetic cargo delivery vehicle 
and iNOS as a potent therapy for the treatment of cancer.
Keywords: Prostate cancer, Nitric oxide, Non-viral gene therapy, Amphipathic peptide, 
iNOS
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Background
Despite recent advances in gene therapy, including the approval of  Glybera® for treat-
ment of lipoprotein lipase deficiency, the safety, cost and patient perception issues that 
have dogged viral strategies for gene therapy persist. This has created opportunities for 
the development of non-viral technologies such as cationic polymers, lipoplexes, or pep-
tides for nucleic acid delivery (Pahle and Walther 2016). RALA is an example of a peptide 
delivery vehicle (McCarthy et al. 2014). RALA is a 30 amino acid amphipathic fusogenic 
peptide (N-WEARLARALARALARHLARALARALRACEA-C) with seven arginines 
in the backbone that facilitate condensation of nucleic acids. When RALA is incubated 
with anionic entities, electrostatic interactions facilitate the spontaneous production of 
nanoparticles. The RALA system is highly tunable with variations in the molar ratios 
of peptide and DNA (the N:P ratio) modulating size and charge characteristics (McCa-
rthy et al. 2014). The RALA nanoparticles readily traverse cell membranes, owing to not 
only the arginines, but also the six leucines, all of which facilitate interaction between 
the nanoparticle and the cell membrane. RALA/DNA nanoparticles penetrate ZR-75-1 
and NCTC-929 cells in both clathrin- and caveolin-mediated manners (McCarthy et al. 
2014). The spatial arrangement of the hydrophilic arginines and hydrophobic leucines in 
the helical structure, enabled by the 12 alanines, confer amphipathicity (McCarthy et al. 
2014). It has also been shown that there is an increase in the α-helicity of RALA with 
a drop in pH from 7.4 to 5.5 which negates entrapment in the endosome and ensures 
delivery of the cargo into the cytoplasm in the presence of an acidic environment 
(McCarthy et al. 2014). The ratio of hydrophilic and hydrophobic residues within RALA 
is critical for functionality. For example, replacement of the hydrophobic residues with 
hydrophilic rendered the resultant peptide (RGSG) incapable of transfection (Udhaya-
kumar et al. 2017). To date, RALA has successfully delivered plasmids encoding reporter 
genes (McCarthy et al. 2014), mRNA (Udhayakumar et al. 2017), siRNA (Bennett et al. 
2015), DNA vaccines (Rajendrakumar et al. 2017), mRNA vaccines (Udhayakumar et al. 
2017) small molecules such as bisphosphonates (Massey et al. 2016) and calcium-based 
bone substitutes (Huerta et al. 2008) demonstrating broad utility.
The genetic origins of cancer render suitability for gene therapeutics such as small 
interfering RNAs, micro RNAs, and CRISPR gene editing tools (Rajendrakumar et  al. 
2017). Indeed, previous research has reported abrogation of the growth of ZR-75-1 
breast cancer xenografts when treated with RALA/pFKBPL (Bennett et  al. 2015), and 
the potency of RALA-delivered inducible nitric oxide synthase (iNOS) in a model of 
breast cancer metastasis. Survival of mice bearing aggressive MDA-MB-231 microme-
tastases was significantly increased by treatment with nanoparticles comprising RALA 
and a constitutively active or a transcriptionally regulated iNOS plasmid (McCrudden 
et al. 2017).
Nitric oxide (·NO) is a gasotransmitter that functions in a range of physiologi-
cal processes, most notable being the regulation of vascular tone (Huerta et  al. 2008). 
The functionality of ·NO in cancer is concentration-dependent, with low physiologi-
cal concentrations (in the nanomolar range) provoking a pathological phenotype, and 
superphysiological concentrations (micromolar) promoting anti-cancer effects (Huerta 
et al. 2008). It has been postulated that iNOS has a role in the pathogenesis of prostate 
cancer (Klotz et al. 1998), with iNOS expression levels proportional to Gleason grade, 
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and indicators of proliferation (Ki-67, mitotic index and S-phase fraction) in prostate 
cancer patients (Aaltoma et al. 2001). However, NOS enzyme [of which there are three 
isoforms—endothelial (e)NOS, neuronal (n)NOS and iNOS] expression levels do not 
necessarily equate to ·NO levels, as other enzymes, including the arginases (Heller 2008) 
and the NOS enzymes’ co-factors BH2 and BH4 (Rabender et  al. 2015) also influence 
·NO levels. It has been proposed that insufficient iNOS levels may actually enable malig-
nancy, by denying hyperproliferative tissues the therapeutic benefit afforded by ·NO 
(Heller 2008).
There is a significant body of evidence supporting the use of iNOS as a therapeutic 
transgene in cancer (Hatefi and Canine 2009; Tambe et al. 2017; Xu et al. 2017; Baltaci 
et al. 2001; Lee et al. 2009; Reschner et al. 2009; Gannon et al. 2010; Siemens et al. 2009; 
Holland et al. 2013). The purpose of this study was to investigate whether systemic deliv-
ery of the RALA/iNOS nanomedicine was therapeutic in a metastatic model of prostate 
cancer.
Methods
Materials
Unless otherwise stated, reagents used were from Sigma (Dorset, UK).
Cell culture
PC-3 prostate cancer cells were purchased from ATCC, and maintained in RPMI-1640 
(Life Technologies) supplemented with 10% fetal bovine serum (PAA). PC-3M-luc-2 
were purchased from Caliper Life Sciences (Buckinghamshire, UK) and maintained in 
RPMI-1640 (Life Technologies) supplemented with 10% fetal bovine serum (PAA). Cells 
were cultivated in 175  cm2 flasks in a humidified incubator; once 80–90% confluency 
was reached, cells were passed to maintain exponential growth. Mycoplasma absence 
was confirmed monthly, using Plasmotest (Invivogen, France).
Plasmid DNA preparation
MAX  Efficiency® DH5α™ Competent Cells transformed with pEGFP-N1 or CMV-iNOS 
plasmids were cultured in a shaking incubator overnight at 37 °C in Luria broth contain-
ing 50 μg/ml ampicillin. Plasmid DNA was isolated and purified using  PureLink® HiPure 
Plasmid Maxiprep Kits (Life Technologies, Paisley, UK), as recommended by the manu-
facturer. Plasmid DNA, dissolved in ultrapure water, was stored at − 20 °C.
Nanoparticle complexation and characterization
RALA, supplied as a desalted lyophilized powder was reconstituted in ultrapure water to 
a stock concentration of 5.8 mg/ml. Aliquots were stored at − 20 °C until use.
Plasmid DNA (pDNA)/RALA nanocomplexes were prepared as described previously 
(McCarthy et  al. 2014); electrostatic interaction between cationic RALA and anionic 
pDNA (30 min at room temperature) facilitates the formation of particles with size and 
charge characteristics suitable for gene delivery (McCarthy et  al. 2014; Bennett et  al. 
2015; McCaffrey et al. 2016). Nanoparticles were complexed at N:P10 (the N:P ratio is 
the molar ratio of positively charged nitrogen atoms in the peptide to negatively charged 
phosphates in the pDNA backbone—at N:P10, 14.5  μg of RALA is complexed with 
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1 μg of DNA); nanoparticle size and charge can be altered by modifying the N:P ratio. 
For analysis of intracellular nanoparticle behavior, nanoparticles were complexed with 
RALA conjugated to fluorescein isothiocyanate (FITC) (Biomatik) and pDNA labeled 
with Cy3 using a Mirus Bio  LabelIt® kit (Cambridge Bioscience, Cambridge, UK)). Nan-
oparticle physicochemical properties were analyzed using a Nano ZS Zetasizer and DTS 
software (Malvern Instruments, UK).
Transmission electron microscopy
RALA/DNA complexes were prepared at N:P 10 with 1 µg pCMV-iNOS in a total vol-
ume of 30  µl. Nanoparticles were loaded onto a carbon-coated copper 400 mesh grid 
(TAAB Laboratories, UK) and allowed to dry. Following drying, the samples were 
stained with 5% uranyl acetate in methanol at room temperature for 1  min, washed 
with 50% ethanol then molecular grade water and allowed to dry again. Nanoparticles 
were imaged using a JEM-1400Plus Transmission Electron Microscope (Joel, USA) at 
an accelerating voltage of 120  kV. Settings were as follows: pinhole (m) 95.5  µm, pin-
hole (airy) 999.4 µm, laser (Argon, visible) On (29%), Laser (DPSS 561, visible) On, laser 
(HeNe 633, visible) On, optical magnification with 10× and a 63× oil immersion objec-
tive, whole section depth was 19.13 µm, with 39 Z sections. Each section was 0.5 µm 
thick. The Z position of the XY image was 24, meaning 12 µm from the top of the cell.
Cellular uptake of FITC‑RALA/Cy3‑pDNA NPs
PC-3M-luc2 were seeded in 24-well plates at  104 cells per well, and incubated over-
night. Cells were conditioned for 2 h in Opti-MEM (Life Technologies) before addition 
of nanoparticle complexes (NPs complexed at N:P 10), and cells were transfected with 
NPs equivalent to 0.5 µg DNA per well. Cellular FITC/Cy3 content was assessed over 
the following 120 h by flow cytometry using a CytoFLEX instrument (Beckman Coulter, 
Labplan, Dublin, Ireland). FITC and Cy3 contents were assessed using manufacturer set-
tings for FITC and PE-A. For the 120-h timepoint, cells were transferred from the wells 
of 24-well plates to those of 6-well plates to allow for proliferation.
Intracellular nanoparticle tracking
PC-3s were seeded in 24-well plates on round coverslips at  104 cells per coverslip, and 
incubated overnight. Cells were conditioned for 2 h in Opti-MEM (Life Technologies) 
before addition of nanoparticle complexes, and cells were transfected for 240 min. Cells 
were fixed using 4% paraformaldehyde in PBS, and coverslips were mounted onto micro-
scope slides using Diamond Antifade with DAPI (Life Technologies). Nanoparticle local-
ization was analyzed by confocal fluorescence microscopy using a Leica SP5 microscope 
and LAS-AF software.
Clonogenic assay
PC-3M-luc2 were seeded in T25 culture flasks at a density of  106 cells per flask, and 
incubated overnight. Following a 2-h starvation in Opti-MEM, cells were transfected 
with RALA/CMV-iNOS nanoparticle formulations, equivalent to 6 μg DNA per flask; 
following a 6-h transfection, transfection media were replaced with normal growth 
medium, and cells were incubated overnight. Following 24  h, cells were trypsinized, 
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counted and plated in triplicate in 6-well plates at 500/1000 cells per well. Plates were 
incubated at 37  °C for 12 days, following which, colonies were fixed and stained using 
0.4% crystal violet (Sigma) in 70% methanol; excess stain was removed by gentle washing 
in water, and once dry, colonies were manually counted.
In vivo immunological response to RALA/pDNA nanoparticles
In order to determine whether nanoparticles complexed of RALA and pDNA provoked 
an immune response, a range of ex vivo assays in C57BL/6 mice were performed. Mice 
were subjected to single or repeated administrations of PBS, RALA/pEGFP-N1 nano-
particles or polyethylenimine (PEI)/pEGFP-N1 nanoparticles. Each injection delivered 
nanoparticles (at N:P 10) equivalent to 10  µg pDNA, and injections were weekly for 
3  weeks. 48  h after each injection, three mice were sacrificed; blood was collected by 
cardiac puncture, and the serum was extracted for analysis of total IgG, IgM, IL-1β, and 
IL-6 using assay kits (Enzo Life Sciences, Exeter, UK). The significance of the impact on 
these mediators was assessed using two-way ANOVA with Dunnett’s multiple compari-
sons test.
To determine whether repeated administrations of nanoparticles provoke neutral-
izing antibody responses, similar administrations were performed. Following sacrifice, 
blood was collected by cardiac puncture, serum was isolated, and sera from triplicate 
mice were pooled, heat inactivated and stored at − 20 °C. 5 × 103 PC-3 were seeded in 
triplicate wells of 96-well plates and allowed to adhere overnight. Cells were starved in 
Opti-MEM for 2 h prior to transfection. Freshly prepared RALA/pEGFP-N1 nanoparti-
cles were incubated for 30 min in sera from mice that had received one of the indicated 
treatments. Sera/nanoparticle mixtures were diluted in Opti-MEM, and used to trans-
fect PC3s. Transfections were for 6 h, following which, Opti-MEM was replaced with 
RPMI-1640. After 48 h, cells were analyzed for eGFP expression by flow cytometry using 
a BD FACSCalibur.
iNOS transgene expression
PC-3M-luc2 were plated  (104 cells per well of a 24-well plate) and allowed to adhere 
overnight, and were transfected with RALA/CMV-iNOS for 6 h, following which Opti-
MEM was replaced with phenol red-free MEM/10% fetal bovine serum. (RPMI-1640 is 
nitrite-rich, which would interfere with the nitrite content assay.) Medium nitrite con-
tent was assayed 48 h later using Greiss test for nitrites (Active Motif, Belgium), follow-
ing the manufacturer’s instructions. Cellular iNOS expression was measured by western 
blot as previously described (Ning et al. 2012).
Establishment of metastatic disease
All animal experiments were carried out in accordance with the Animal (Scientific Pro-
cedures) Act 1986 and conformed to the current UKCCCR guidelines. Mice were bred 
in-house and maintained using the highest possible standard of care, and priority was 
given to their welfare.
Mice (6–8  weeks old) were anesthetized using isoflurane (3% in  O2) and restrained 
using surgical adhesive tape in a supine position. Thoracic fur was removed using Veet 
hair removal cream. Using a 1-ml syringe/26G needle, mice were inoculated with  105 
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PC-3M-luc2 in 100 μl PBS via the left cardiac ventricle (Lim et al. 2011)—the cell sus-
pension was gently injected into the ventricle, following which the needle was held 
in place for 10  s to minimize leakage from the ventricle. Mice were imaged using an 
IVIS200 (Xenogen) instrument to confirm appropriate ventricular delivery. Mice were 
injected intraperitoneally with 150  mg/kg d-luciferin; following a 15-min incubation, 
mice were anesthetized using isoflurane and imaged. Appropriate left ventricular deliv-
ery is characterized by luminescence throughout the body, while inappropriate delivery 
is characterized by luminescence that is limited to the thoracic cavity.
iNOS gene therapy
Gene therapy treatment began 48-h post-inoculation, with mice receiving treatments 
twice weekly, totaling five treatments. RALA/CMV-iNOS nanocomplexes (correspond-
ing to 5 × 10 μg DNA per mouse) at N:P 10 were delivered via the tail vein. Solvent (PBS) 
and vehicle (RALA equivalent to the mass of RALA used in the gene therapy regimen) 
controls were also performed.
Mice were monitored for micrometastases development using routine IVIS imag-
ing, as well as body mass measurement. A loss of 20% original body mass was deemed 
a b c
d
e
f
Fig. 1 RALA/pDNA nanoparticles are suitable for rapid uptake by PC3 prostate cancer cells. a Nanoparticles 
comprising RALA and pEGFP-1 plasmid DNA have size and charge properties suitable for cellular entry. 
Conjugation of Cy3 to pDNA does not impact size or charge of nanoparticles, while nanoparticles comprising 
FITC-conjugated RALA and CY3-conjugated pDNA are of a similar size, but more positively charged. b TEM of 
RALA/CMV-iNOS nanoparticles at N:P 10; scale bar 200 µm. c FITC-RALA/Cy3-pDNA nanoparticles are rapidly 
taken up by PC3 prostate cancer cells. d Orthogonal sectioning of PC3 cells after 4-h transfection with RALA/
Cy3-CMV-iNOS nanoparticles. e Representative dot plots of FITC/Cy3 positivity in PC3s transfected with 
FITC-RALA/Cy3-pDNA nanoparticles. f PC3s transfected with FITC-RALA/Cy3-pDNA nanoparticles rapidly 
accumulate and retain both fluorophores up to 1440 min following transfection; FITC content is lost more 
rapidly than Cy3, with 25% of cells Cy3-positive 7200-min (5 days) post-transfection. Datapoints represent 
mean ± SEM; N = 3
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sufficient to necessitate sacrifice of the mouse. The degree of whole body luminescence 
in mice was determined using Living Image software (Perkin Elmer).
Statistics
All statistics were performed using GraphPad Prism, version 6.0 g for Mac OS X. The 
tests used are described throughout.
Results
Physicochemical characterization of RALA/pDNA NPs
Incubation of plasmid DNA with RALA provoked spontaneous complexation of the two 
components into cationic nanoscale particles. Labeling pDNA with Cy3 before complex-
ing NPs did not significantly impact the physicochemical properties of NPs (Fig. 1a). Use 
of FITC-conjugated RALA to condense Cy3-labeled pDNA into NPs afforded the NPs a 
higher zeta potential than those formed using unlabeled peptide/DNA, although the NP 
size was unaffected (Fig. 1a). Figure 1b shows a TEM micrograph of RALA/CMV-iNOS 
nanoparticles at N:P 10; scale bar represents 200 µm. The apparent diameters of nano-
particles in the TEM image appear to support the diameter data produced by dynamic 
light scattering. Figure 1c shows the uptake of RALA/Cy3-DNA nanoparticles 4-h post-
transfection. Orthogonal sectioning was used to determine the cellular localization 
of fluorescent DNA; at 4  h, DNA was strongly associated with the cell, and could be 
seen to be crossing the cell membrane. PC3M-luc2 cells also rapidly took up nanopar-
ticles labeled with both fluorophores (FITC-RALA/Cy3-pDNA—Fig. 1d–f). The profile 
of cell fluorophore contents progressed in parallel for the first 24 h (1440 min); at 48 h 
a b
c d
Fig. 2 Validation of transgene expression in PC3s. a, b PC3s were transfected with RALA/pEGFP-N1 
(comprising 0.5 μg DNA) at N:P10 for 6 h. Cells were analyzed for GFP expression 48-h post-transfection 
using immunoblotting, and fluorescence microscopy. c, d PC3s were transfected with RALA/CMV-iNOS 
(comprising 0.5 μg DNA) at N:P10 for 6 h. Cells were analyzed for iNOS expression 48-h post-transfection 
using immunoblotting, for ·NO generation by Greiss test. Datapoints represent mean ± SD; N = 3
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(2880  min), and more pronounced at 120  h (7200  min), Cy3 content was appreciably 
higher than that of FITC, indicating that the RALA vehicle is discarded, but the pDNA 
is retained. By 120 h, the Cy3 signal is probably diluted by mitosis, with daughter cells 
not inheriting the Cy3 label (Fig.  1d, f ). Figure  1e contains representative dotplots of 
FITC/Cy3 content in untransfected and transfected cells with FITC-RALA/Cy3-pDNA 
(360  min), while Fig.  1f summarizes the pattern of fluorophore content in transfected 
cells at all timepoints.
Gene expression following RALA/pDNA transfection
PC3  M-luc2 cells transfected with RALA/pEGFP-N1 displayed eGFP expression  48-h 
post-transfection (Fig.  2a, b). When PC3  M-luc2 were transfected with RALA/CMV-
iNOS, protein was detected 48-h post-transfection (Fig. 2c), and medium nitrate content 
was 2.2-fold higher than that seen in control conditions; RALA/pEGFP-N1 transfection 
did not affect extracellular nitrate levels (Fig. 2d).
RALA/CMV‑iNOS treatment inhibits the clonogenicity of PC3M‑luc2
PC3M-luc2 cells transfected with RALA/CMV-iNOS had a significant reduction 
(61.1 ± 8.5%) in clonogenic colonies compared to untransfected cells (100%). Transfec-
tion of PC3M-luc2 cells with RALA/pEGFP-N1 (83.0 ± 19.1%) did not affect clonogenic-
ity (Fig. 3).
Treatment of C57BL/6 mice with RALA/pEGFP‑N1 NPs does not affect circulating IgG, IgM, 
or IL‑1β and IL‑6 levels
The impact of RALA/pDNA or PEI/pDNA compared to PBS treatment on circulating 
IgG, IgM, IL-1β, and IL-6 levels are summarized in Fig. 4a–d, and in Table 1. 
RALA/pEGFP‑N1 NPs provoke no neutralizing antibody response in immunocompetent 
mice
Incubation of RALA/pEGFP-N1 NPs with sera from C57BL/6 mice previously treated 
with RALA/pEGFP-N1 did not appreciably affect transfection ability of the NPs. 
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Fig. 3 Validation of transgene expression in PC3s. PC3-luc2M cells overexpressing iNOS form fewer 
clonogenic colonies than control. Datapoints represent mean ± SEM; N = 3
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One-way ANOVA with Dunnett’s correction for multiple comparisons was used to 
compare sera from nanoparticle-treated mice with other treatments. In no case did 
incubation in sera from nanoparticle-treated mice lessen eGFP expression (Fig. 5a–c). 
Increasing serum concentration slightly abrogated the transfection ability of NPs, 
although the relevance of this is questionable. Any inhibition of transfection ability 
cannot be attributed to NP neutralization, as this abrogation was observed in all sera, 
including FBS, which had not been pre-exposed to nanoparticles. The ‘significance’ of 
transfection inhibition between mice that received nanoparticles and those that received 
PBS at week 1 can likely be explained by the absence of a 10% serum datapoint in the 
PBS group.
RALA/CMV‑iNOS therapy delays the progression of metastatic prostate cancer
Treatment of mice bearing metastatic foci of PC3M-luc2 with RALA/CMV-iNOS signif-
icantly increased median survival from 90.5 days (control) to 141 days (p = 0.005). RALA 
alone did not significantly alter median survival (p = 0.0824) (Fig. 6a). Mice that received 
RALA/CMV-iNOS treatment lost weight and developed bioluminescence more slowly 
than control or RALA-treated counterparts. Figure  6b represents the degree of rela-
tive weight loss of individual mice whose post-inoculation survival was closest to the 
relevant treatment’s median value; Fig.  6c represents bioluminescence accumulated in 
the same mice. For cumulative weight loss and bioluminescence accumulation see Sup-
plementary Figs.  1 and 2. 50% of the mice in the RALA/CMV-iNOS treatment group 
were sacrificed without having lost 20% original body weight. Similarly, these mice also 
progressed though the study developing considerably less bioluminescence than others 
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Fig. 4 Immune response of C57BL/6 mice injected with PBS, PEI/pDNA, or RALA/pDNA nanoparticles (10 µg 
pDNA at N:P10). Mice received one injection per week for 3 weeks. 48 h after each injection three mice were 
sacrificed and the serum was assayed for IgG (a), IgM (b), IL-1β (c), and IL-6 (d) content. Datapoints represent 
mean ± SEM; N = 3
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in the same treatment group. In that respect, these mice could be considered to be com-
plete responders, being devoid of the two indicators of disease that were studied, namely 
weight loss and bioluminescence. Figure 6d displays the evolution of metastatic foci in 
Table 1 Comparisons of  treatment compared to  PBS only  on  circulating IgG, IgM, IL-1β 
and IL-6 levels
*p < 0.05; **p < 0.01; ***p < 0.001
Timepoint Comparison Mean difference 95% CI of diff. Significance
IgG
 Week 1 PBS v PEI/pDNA 10.40 4.20 to 16.61 **
PBS v RALA/pDNA 10.54 4.33 to 16.75 **
 Week 2 PBS v PEI/pDNA − 0.02 − 6.23 to 6.20 ns
PBS v RALA/pDNA 0.03 − 6.18 to 6.24 ns
 Week 3 PBS v PEI/pDNA − 13.89 − 20.1 to − 7.68 ***
PBS v RALA/pDNA − 5.07 − 11.28 to 1.15 ns
IgM
 Week 1 PBS v PEI/pDNA 2.66 − 23.05 to 28.37 ns
PBS v RALA/pDNA − 2.18 − 27.89 to 23.52 ns
 Week 2 PBS v PEI/pDNA − 10.44 − 36.15 to 15.27 ns
PBS v RALA/pDNA − 11.99 − 37.7 to 13.72 ns
 Week 3 PBS v PEI/pDNA − 30.79 − 56.5 to − 5.08 *
PBS v RALA/pDNA − 20.98 − 46.69 to 4.73 ns
Il-1β
 Week 1 PBS v PEI/pDNA 4.20 − 3.29 to 11.69 ns
PBS v RALA/pDNA 6.77 − 0.72 to 14.26 ns
 Week 2 PBS v PEI/pDNA − 1.94 − 9.43 to 5.55 ns
PBS v RALA/pDNA 4.19 − 3.31 to 11.68 ns
 Week 3 PBS v PEI/pDNA − 4.73 − 12.22 to 2.76 ns
PBS v RALA/pDNA − 3.27 − 10.76 to 4.22 ns
IL6
 Week 1 PBS v PEI/pDNA − 27.61 − 52.87 to − 2.35 *
PBS v RALA/pDNA − 26.24 − 51.50 to 0.97 *
 Week 2 PBS v PEI/pDNA 10.61 − 14.66 to 35.87 ns
PBS v RALA/pDNA − 2.41 − 27.67 to 22.85 ns
 Week 3 PBS v PEI/pDNA 17.74 − 7.52 to 43.00 ns
PBS v RALA/pDNA 2.80 − 22.47 to 28.06 ns
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Fig. 5 Administration of RALA/pEGFP-N1 nanoparticles to immunocompetent mice does not provoke a 
neutralizing antibody response. Flow cytometric analysis of GFP in PC3s after incubation of RALA/pEGFP-N1 
nanoparticles with sera from C57BL/6 mice that received the indicated treatment (PBS/DNA/RALA/NPs) 
weekly for up to 3 weeks (a Week 1; b. Week 2; c. Week 3). *p < 0.05, **p < 0.01 compared to expression 
elicited by RALA/pEGFP-N1 nanoparticles (NP) that had been incubated in sera from mice that had received 
nanoparticles (multiple comparisons ANOVA)
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the individual control and RALA/CMV-iNOS-treated mice whose physical and bio-
chemical data are presented in Fig. 6b, c.
Discussion
It was previously reported that RALA/iNOS nanoparticulate gene therapy produced 
·NO production in  vitro, and improved survival following systemic administration 
in a model of breast cancer metastasis (McCrudden et  al. 2017). The results reported 
here reinforce those findings in prostate cancer. The improvement in survival in this 
prostate cancer model was much higher (56% increase in median survival in the PC-3 
model versus a 27% increase in median survival in the breast cancer model), although 
an explanation for this has not been ascertained. MDA-MB-231 breast cancer cells are 
a notoriously aggressive model of breast cancer, and the progression of disease was 
faster in that model (the median survival of control mice in this study was 90.5  days, 
but only 31.5 days in the breast model), which may account for the observed differences 
(McCrudden et al. 2017).
Therapeutic ·NO is most commonly achieved using a donor drug such as organic 
nitrates, metal-NO complexes, S-nitrosothiols, sydnonimines, diazeniumdiolates 
(NONOates), and ·NO-drug hybrids (Huerta et  al. 2008). In contrast, our strategy of 
using a simple peptide and native DNA as a therapeutic should provoke fewer drug-
related side effects than these donor agents or viral vectors would (Hatefi and Canine 
2009). RALA/CMV-iNOS nanoparticles were in the same size range as nanoparticles 
used by others in prostate cancer nucleic acid therapies (Tambe et  al. 2017; Xu et  al. 
a b
c d
Fig. 6 Treatment with RALA/CMV-iNOS improves survival of PC3-luc2M metastases-bearing mice. a Survival 
of metastases-bearing mice. N ≥ 5 (control, RALA) or 11 (RALA/CMV-iNOS). b Weight loss of exemplar mice. 
c Total bioluminescence in exemplar mice; inverted triangles denote treatment timepoints. d IVIS images 
of mice (control and RALA/CMV-iNOS) showing bioluminescence accumulation at indicated timepoints 
post-implantation
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2017). Nanoparticles delivered intravenously are readily taken up by organs such as the 
lungs, liver, and spleen, so these organs are particularly susceptible to possible off-target 
side effects. Expression of iNOS was not assessed in these organs although it has been 
previously shown that the lungs and liver strongly express transgenes following RALA/
DNA delivery via the tail vein (McCarthy et al. 2014). Although no harmful side effects 
were observed, strategies to prevent iNOS expression in non-target tissues, such as tran-
scriptional targeting (McCrudden et al. 2017), are still an attractive proposition.
iNOS and ·NO may be controversial agents to employ for the treatment of cancer. 
Correlations between iNOS and prostate cancer have been described previously (Klotz 
et  al. 1998). Indeed, high-grade prostatic intraepithelial neoplasia (PIN) and prostatic 
carcinoma samples had higher iNOS expression than low-grade PIN or benign pros-
tatic hyperplasia specimens (Baltaci et al. 2001). Polymorphisms in the iNOS gene were 
associated with prostate cancer aggressiveness, although the functional consequences 
of these polymorphisms are unclear (Lee et  al. 2009). However, despite these correla-
tions, an argument exists that cancers develop as a result of failure to achieve sustained 
high-level (and therefore therapeutic) ·NO production, rather than being consequent of 
iNOS expression. Arginase, which depletes iNOS’s substrate, l-arginine (Heller 2008), is 
overexpressed in prostate cancer tissue (Reschner et al. 2009). As arginases may inter-
fere with the therapeutic activity of iNOS, it is possible that selective inhibition of argin-
ase activity could further boost the potency of therapeutic strategies that aim to achieve 
elevated ·NO levels, such as our RALA/iNOS therapy. The first trial assessing the safety 
and tolerability of a selective arginase inhibitor, CB-1158, is currently recruiting patients 
with solid tumors (NCT02903914). Indeed, the therapeutic benefit of androgen depriva-
tion therapy in patients may be in-part down to inhibition of the expressions of both 
arginases 1 and − 2 (Gannon et  al. 2010). Other mediators that affect iNOS, such as 
N-chlorotaurine or N-bromotaurine, have been shown to impact upon the concentra-
tion and (patho)physiology of intratumoral ·NO (Heller 2008).
A concern associated with the delivery of ·NO is the possibility that vasodilation 
may manifest as hypotension. The present study did not find any evidence of toxicity of 
RALA/CMV-iNOS therapy consistent with hypotension, nor did our previous study of 
RALA/iNOS strategies in breast cancer (McCrudden et al. 2017). Non-localized delivery 
has been observed to produce impressive therapeutic efficacy in the past—a nitroglyc-
erin-releasing transdermal patch almost trebled the PSA doubling time in a cohort of 
prostate cancer patients post-surgery or—radiotherapy (Siemens et al. 2009). Notwith-
standing that, a strategy to limit ·NO release to the target tissue to preclude systemic 
toxicities is attractive. Several ·NO donor drugs have been designed to include strategies 
to ensure ·NO production is limited to the tumor, including β-galactosidase-provoked 
release of ·NO/HNO from IPA/NO (Holland et al. 2013), nitroreductase-dependent ·NO 
release from 1-(2-methylpiperidin-1-yl)diazen-1-ium-1,2-diolate (Sharma et  al. 2013), 
and the preferential release of ·NO from RRx-001 in hypoxia (Ning et al. 2012). The dis-
tinctive tumor phenotype can be exploited for targeting genetic therapies also; function-
alization of nanoparticles with anti-prostate-specific membrane antigen (PSMA) RNA 
aptamer facilitated precise miRNA delivery to xenografts following systemic administra-
tion, and impressive tumor growth delay (Binzel et al. 2016). Xu and colleagues used a 
pH-responsive polymer to provoke nanoparticle disassembly and siRNA delivery in the 
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acidic tumor microenvironment, and reported marked tumor growth delay in an LNCaP 
xenograft model of prostate cancer (Xu et al. 2017).
The use of the human osteocalcin promoter to facilitate transcriptional targeting, 
thereby limiting iNOS transgene expression to tumors with elevated RUNX2 expression 
has also been employed (McCrudden et al. 2017). Future studies will focus on the func-
tionalization of RALA/DNA nanoparticles to facilitate homing to tumors. The benefits 
of vehicle modification were demonstrated by Lee and colleagues, who through nano-
particle modification (thiol-modified glycol chitosan), produced a nucleic acid-delivery 
vehicle that bypassed normal tissue, preferentially delivering to PC-3 xenografts. The 
unembellished nanoparticles had modest potency, but replacement of the chitosan with 
the thiolated chitosan markedly improved the anti-tumor benefit of systemically deliv-
ered siVEGF (Lee et al. 2017).
Future directions and conclusions
For further evaluation of the RALA platform, a more comparative study could be per-
formed with respect to other liposomal or polymeric delivery systems to not only com-
pare efficacy but also toxicity both in  vitro and in  vivo. Additionally, a wider panel of 
cytokine markers could be measured in vivo to support the initial findings of no signifi-
cant inflammatory response. To develop this therapy further, variables such a dose, tim-
ing and duration required optimization. Despite no adverse toxicity with constitutively 
drive iNOS, targeted delivery could be considered. This could be achieve via transcrip-
tional targeting of the gene (McBride et al. 2016) or by amending the RALA platform to 
target tumors using ligands such as TMTP-1 (Coulter et al. 2010). Nevertheless, the data 
presented in this study demonstrate that the DNA persists in the cell after the RALA is 
disassociated, that RALA does not produce any neutralizing antibodies and that IgG and 
IgM effects are negligible following repeated injection. There is also a clear anti-cancer 
effect of RALA/iNOS gene therapy for metastatic prostate cancer following both in vitro 
and in  vivo studies. Although the mechanism by which ·NO achieves this anti-tumor 
effect in PC3 metastases has not yet been determined, previous studies have indicated 
that the production of dinitrogen trioxide is responsible for toxicity (Ali et  al. 2013), 
inhibition of angiogenesis or recruitment of cytotoxic T cells (Singh and Gupta 2011). 
This research supports the continued development of iNOS gene therapy in the non-
viral RALA delivery platform.
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